These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 16518961

  • 1. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [Abstract] [Full Text] [Related]

  • 2. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S, el Filal KM, Sodqi M, Loundou A, Luchini S, Cleary S, Moatti JP, Himmich H.
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA.
    AIDS; 2004 Dec 03; 18(18):2411-8. PubMed ID: 15622317
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
    Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Schwartz A, Sanders GD, Owens DK.
    AIDS; 2006 Nov 14; 20(17):2207-15. PubMed ID: 17086061
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa.
    Stinson K, Boulle A, Coetzee D, Abrams EJ, Myer L.
    Trop Med Int Health; 2010 Jul 14; 15(7):825-32. PubMed ID: 20497405
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
    Mauskopf J, Lacey L, Kempel A, Simpson K.
    Am J Manag Care; 1998 Jul 14; 4(7):1004-12. PubMed ID: 10181990
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.